<DOC>
	<DOCNO>NCT00473460</DOCNO>
	<brief_summary>Moxifloxacin , test approximately 60 study centre 15 country determine drug , take periodically addition patient normal treatment , effective reduce number flare-ups chronic bronchitis . Approximately 1132 subject participate , expect study run 2 year order reach goal . The patient individual involvement study 17 month . Moxifloxacin compare placebo drug ( active ingredient ) . The study medication ( moxifloxacin placebo ) take addition patient normal medication chronic bronchitis . In addition first clinic visit , call screen visit , patient require come back clinic ten study visit , every 8 week . At first visit study co-ordinator provide date visit . Over period 48 week patient return clinic 6 occasion receive study medication take five day , addition normal treatment chronic bronchitis . After time patient enter follow period 24 week , come clinic assessment continue take normal medication receive study drug . A complete medical history take first visit , include patient past current smoking habit . A breath test perform assess well lung function . In addition , also ask provide sputum sample microbiological examination identify bacteria present sample . The patient must able provide sputum sample screen visit . If patient meet inclusion / exclusion criterion study , allocate randomly one follow treatment group second visit.- Treatment group 1 : Receives moxifloxacin orally daily five days.- Treatment group 2 : Receives match placebo daily five days.In visit ( four week clinic visit ) , study site co-ordinator contact patient check well . If patient doctor decides stop patient participation trial reason , patient require return clinic physical examination , take breath test , provide sputum sample ( possible ) blood sample take .</brief_summary>
	<brief_title>Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Male female outpatient &gt; /= 45 year Subjects suffer chronic bronchitis FEV1 &lt; /= 70 % FEV1/FVC &lt; /= 70 % predicted age , height sex No document episode AECB ( require treatment ) within 6 week randomization experience exacerbation time screen Sputum production day , even exacerbation free Subjects present least two documented ( i.e . require antibiotic and/or systemic steroid administration ) acute exacerbation episode last 12 monthsIf receive chronic therapy inhale long act bronchodilator and/or inhale systemic steroid , treatment must remain stable precede 6 week prior screen Smoking history least 20 packyears Subjects willing able give fully inform write consent Subjects contraindication moxifloxacin Known bronchial carcinoma , pulmonary tuberculosis , cystic fibrosis , document chronic bronchial asthma diffuse bronchiectasis Subjects actively participate intensive pulmonary rehabilitation program Subjects known history chronic colonization pathogenic organism resistant moxifloxacin , e.g . Pseudomonas spp , MRSA No systemic inhale antibiotic therapy 6 week prior screen long term antibiotic usage Subjects require home ventilatory support COPD tracheostomy situ ( subject require home/potable oxygen therapy CPAP sleep apnea include )</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Chronic bronchitis</keyword>
	<keyword>Chronic obstructive pulmonary disease</keyword>
	<keyword>Acute exacerbation chronic bronchitis</keyword>
	<keyword>Prevention therapy</keyword>
	<keyword>Antibiotics</keyword>
	<keyword>Fluoroquinolone</keyword>
	<keyword>Moxifloxacin</keyword>
	<keyword>AECB</keyword>
</DOC>